Tell us briefly what is your research about My lab is interested in understanding the differences between the various genetic subtypes of lung cancer. We know based on a lot of genome sequencing studies that patients with lung cancer have a lot of different mutations due to smoking and there is a lot of heterogeneity […]Continue Reading... Comments Off on Dr. Thales Papagiannakopoulos
Dr. Aristotelis Tsirigos is an Associate Professor of Pathology and Director of the Applied Bioinformatics Laboratories at the NYU School of Medicine. He received his Ph.D. in Computer Science from Courant Institute of New York University in January 2006, and his B.S. from the National Technical University of Athens, Greece in 1998. Dr. Tsirigos has […]Continue Reading... Comments Off on Dr. Aristotelis Tsirigos
Petros Grivas, M.D. Ph.D., is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the Clinical Director of the Genitourinary Cancers Program at the University of Washington and Associate Professor in the Dept. of Medicine, Division of Oncology. He is also an Associate Member at the Fred Hutchinson Cancer Research Center […]Continue Reading... Comments Off on Dr. Petros Grivas
Dr. Evripidis Gavathiotis is an Associate Professor in the Department of Biochemistry and the Department of Medicine at Albert Einstein College of Medicine. He is a faculty member of the Einstein’s Center of Experimental Therapeutics, the Albert Einstein Cancer Center, the Wilf Family Cardiovascular Research Institute, the Institute of Aging Research and the Gottesman Institute for Stem Cell Biology and Regenerative Medicine. Dr. Gavathiotis grew up in Athens, Greece and received his bachelor degree in Chemistry from the University of Crete in 1998. He received his Ph.D in Biological Chemistry from the University of Nottingham in 2002 studying the structural mechanism of DNA-binding anti-cancer drugs. He worked at De Novo Pharmaceuticals in the Drug Design and Discovery department applying in silico drug design and lead optimization approaches for several therapeutic targets. Dr. Gavathiotis pursued post-doctoral fellowships at the Rockefeller University studying the structural and molecular biology of apoptosis signaling and at the Dana-Farber Cancer Institute and Harvard Medical School, where he studied the BCL-2 family of proteins in apoptosis and cancer. In 2009, Dr. Gavathiotis was appointed Instructor in the Department of Pediatrics at Harvard Medical School and then joined the faculty of Einstein in 2011. Dr. Gavathiotis has received numerous honors and awards throughout his career including the NIH Pathway to Independence Award, the AHA Scientist Development Award and Scholar Awards from the Gabrielle’s Angel Foundation for Cancer Research, the Sidney Kimmel Foundation for Cancer Research and the Alexandrine and Alexander L. Sinsheimer Foundation.Continue Reading... Comments Off on Dr. Evripidis Gavathiotis
Dr. Patrinos joined NYU-Poly from Synthetic Genomics Inc. (SGI), a privately held company founded in 2005 applying genomic-driven commercial solutions that address global energy and environmental challenges. At SGI he served as President and as Senior Vice President for Corporate Affairs. Prior to joining SGI, Dr. Patrinos was instrumental in advancing the scientific and policy framework underpinning key governmental energy and environmental initiatives while serving as associate director of the Office of Biological and Environmental Research in the U.S. Department of Energy’s Office of Science. Dr. Patrinos played a historic role in the Human Genome Project, the founding of the DOE Joint Genome Institute and the design and launch of the DOE’s Genomes to Life Program, a research program dedicated to developing technologies to use microbes for innovative solutions to energy and environmental challenges.Continue Reading... Comments Off on Interview with Aristides A.N. Patrinos, Ph.D.
The HBA would like to kick off the new section of the site with the republishing of an interview of Dr. K. Drosatos who is a founding member of the HBA, has been with HBA since its inception and has been supporting the Association in all its steps. The interview was first published in the Greek-American publication “Cosmopolis” in December 2010 (Vol. 2, No. 1). Since then we did some edits to reflect the current achievements and direction of HBA. Dr. Drosatos is currently an Assistant Professor in Pharmacology & Center for Translational Medicine at Temple University. His research aims to elucidate the mechanisms that underlie sepsis-induced cardiac energy deprivation and coordinate with clinical scientists to propose potential treatments for improvement of heart function in septic patients. The findings of his studies can be extrapolated to other types of cardiac dysfunction and propose novel therapies for the treatment of heart failure (HF). In addition, we are exploring the cardiac metabolic profile and its contribution in the phenotype of other diseases, such as the Spinal Muscular Atrophy (SMA).Continue Reading... Comments Off on Interview with Dr. Konstantinos Drosatos, HBA-USA founder